50,000 Shares in DBV Technologies S.A. (NASDAQ:DBVT) Acquired by Boxer Capital Management LLC

Boxer Capital Management LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission.

DBV Technologies Trading Down 4.4 %

DBVT opened at $8.61 on Friday. DBV Technologies S.A. has a 1-year low of $2.20 and a 1-year high of $9.89. The company has a market cap of $235.83 million, a price-to-earnings ratio of -1.91 and a beta of -0.08. The company's fifty day moving average price is $6.28 and its two-hundred day moving average price is $4.62.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. The company had revenue of $0.51 million for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. As a group, equities analysts forecast that DBV Technologies S.A. will post -7.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on DBVT. StockNews.com started coverage on shares of DBV Technologies in a research note on Thursday. They issued a "hold" rating for the company. JMP Securities upped their price target on DBV Technologies from $10.00 to $15.00 and gave the stock a "market outperform" rating in a research note on Thursday.

DBV Technologies Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.